BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
Source: SeekingAlpha
2025-10-27 11:17:51 ET
BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 October 27, 2025 8:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-0.28% G/L:
$68.82 Last:
846,114 Volume:
$70.43 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
